Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy

Abstract

ObjectiveNumerous studies have suggested that microRNA-126 (miR-126) is involved in development of various cancer types as well as in malignant proliferation and invasion. However, its role in human prostate cancer (PCa) is still unclear. The aim of this study was to investigate miR-126 expression in PCa and its prognostic value for PCa patients undergoing radical prostatectomy.MethodsA series of 128 cases with PCa were evaluated for the expression levels of miR-126 by quantitative reverse-transcription PCR (qRT-PCR). Kaplan-Meier analysis and Cox proportional hazards regression models were used to investigate the correlation between miR-126 expression and prognosis of PCa patients.ResultsCompared with non-cancerous prostate tissues, the expression level of miR-126 was significantly decreased in PCa tissues (PCa vs. non-cancerous prostate: 1.05 ± 0.63 vs. 2.92 ± 0.98, P < 0.001). Additionally, the loss of miR-126 expression was dramatically associated with aggressive clinical pathological features, including advanced pathological stage (P = 0.001), positive lymph node metastasis (P = 0.006), high preoperative PSA (P = 0.003) and positive angiolymphatic invasion (P = 0.001). Moreover, Kaplan–Meier survival analysis showed that PCa patients with low miR-126 expression have shorter biochemical recurrence (BCR)-free survival than those with high miR-126 expression. Furthermore, multivariate analysis indicated that miR-126 expression was an independent prognostic factor for BCR-free survival after radical prostatectomy.ConclusionThese findings suggest for the first time that the loss of miR-126 expression may play a positive role in the malignant progression of PCa. More importantly, the downregulation of miR-126 may serve as an independent predictor of BCR-free survival in patients with PCa.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1740080792113255.

Expression of miRNAs in non-small-cell lung carcinomas and their association with clinicopathological features

“…Furthermore, expression of miR-126 was found to be increased in metastatic colorectal cancer patients responding to the first-line treatment with capecitabine and oxaliplatin, compared to the patients showing to response [55]. In prostate cancer, miR-126 was reported to be downregulated and its expression level was associated with tumor advance stage and positive lymph node [56].…”

Monitoring of platelet function parameters and microRNA expression levels in patients with prostate cancer treated with volumetric modulated arc radiotherapy

“…It has been demonstrated that miRNAs can enter into systemic circulation via certain mechanisms, including exosome secretion, cell death and blebbing, and that these circulating miRNAs could be used as potential markers for and in the follow-up of certain diseases (24). So far, studies have focused on the changes of miRNA expression levels associated with cancer (1,61). However, to the best of our knowledge there are no studies that have investigated the effects of radiation on platelet miRNA expression.…”

“…Prostate cancer was a common global malignancy among men in 2012 (1,2). Ionizing radiation is used to treat various types of cancer (3), including localized prostate cancer (4).…”

MicroRNA-126 modulates the tumor microenvironment by targeting calmodulin-regulated spectrin-associated protein 1 (Camsap1)

“…Loss of miR-126 has been observed in many cancers, such as breast cancer (8), lung cancer (10) and prostate cancer (17). The decreased expression of miR-126 was associated with poor metastasis-free survival of breast cancer patients (18).…”